Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice

Cancer Research

Volumn 65, Issue 1, 2005, Pages 85-91

  Houghtaling, Scott ^a   Granville, Laura ^b   Akkari, Yassmine ^a   Torimaru, Yumi ^a   Olson, Susan ^a   Finegold, Milton ^b   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BREAST ADENOCARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; EPITHELIUM TUMOR; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 GENE; FEMALE; FIBROBLAST; GENE; GENE MUTATION; GENE REARRANGEMENT; GENETIC COMPLEMENTATION; HETEROZYGOSITY; KNOCKOUT MOUSE; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; SARCOMA;

ANEUPLOIDY; ANIMALS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; GENE REARRANGEMENT; GENES, P53; GENETIC COMPLEMENTATION TEST; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE DETECTION; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS;

EID: 11244341619     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Tischkowitz MD, Hodgson SV. Fanconi anaemia. J Med Genet 2003;40:1-10.
2. Alter BP, Greene MH, Velazquez I, Rosenberg PS. Cancer in Fanconi anemia. Blood 2003;101:2072.
3. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003;97:425-40.
4. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for two new genetic subtypes. Blood 2004;103:2498-503.
5. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996;14:320-3.
6. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992;356:763-7.
7. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
8. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001;7:241-8.
9. de Winter JP, Leveille F, van Berkel CG, et al. Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet 2000;67:1306-8.
10. de Winter JP, Rooimans MA, van Der Weel L, et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000;24:15-6.
11. de Winter JP, Waisfisz Q, Rooimans MA, et al. The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet 1998;20:281-3.
12. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003;35:165-70.
13. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:1548-51.
14. Hirsch B, Shimamura A, Moreau L, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004;103:2554-9.
15. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
16. Taniguchi T, Garcia-Higuera I, Andreassen PR, et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002;100:2414-20.
17. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62.
18. Wang X, Andreassen PR, DAndrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004;24:5850-62.
19. Meetei AR, Yan Z, Wang, W. FANCL replaces BBCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 2004;3:179-81.
20. Rothfuss A, Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BBCA pathway. Mol Cell Biol 2004;24:123-34.
21. Cheng NC, van de Vrugt HJ, van der Valk MA, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 2000;9:1805-11.
22. Noll M, Battaile KP, Bateman R, et al. Fanconi anemia group A and C double-mutant mice. Functional evidence for a multi-protein Fanconi anemia complex. Exp Hematol 2002;30:679-88.
23. Wong JC, Alon N, McKerlie C, et al. Targeted disruption of exons 1 to 6 of the Fanconi anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum Mol Genet 2003;12:2063-76.
24. Whitney MA, Royle G, Low MJ, et al. Germ cell defects and hematopoietic hypersensitivity to γ-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 1996;88:49-58.
25. Chen M, Tomkins DJ, Auerbaeh W, et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996;12:448-51.
26. Yang Y, Kuang Y, De Oca RM, et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 2001;98:3435-40.
27. Koomen M, Cheng NC, van de Vrugt HJ, et al. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. Hum Mol Genet 2002;11:273-81.
28. Houghtaling S, Timmers C, Noll M, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003;17:2021-35.
29. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
30. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
31. Harvey M, McArthur MJ, Montgomery CA Jr, et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993;5:225-9.
32. Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003;95:1718-21.
33. Lowy DR, Gillison ML. A new link between Fanconi anemia and human papillomavirus-associated malignancies. J Natl Cancer Inst 2003;95:1648-50.
34. Cressman VL, Backlund DC, Hicks EM, et al. Mammary tumor formation in p53- and BRCA1-deficient mice. Cell Growth Differ 1999;10:1-10.
35. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999;22:37-43.
36. Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001;28:266-71.
37. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001;20:7514-23.
38. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
39. Freie B, Li X, Ciccone SL, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 2003;102:4146-52.
40. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
41. Akkari YM, Bateman RL, Reifsteck CA, Olson SB, Grompe M. DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol Cell Biol 2000;20:8283-9.
42. Akkari YM, Bateman RL, Reifsteck CA, et al. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol Genet Metab 2001;74:403-12.
43. Frohnmayer LaD. Fanconi anemia: a handbook for families and their physicians, 3rd ed. Eugene (OR): Fanconi Anemia Research Fund, Inc.; 2000.
44. Hanson H, Mathew CG, Docherty Z, Mackie Ogilvie C. Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach. Cytogenet Cell Genet 2001;93:203-6.
45. Ball SE, Gibson FM, Rizzo S, et al. Progressive telomere shortening in aplastic anemia. Blood 1998;91:3582-92.
46. Leteurtre F, Li X, Guardiola P, et al. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol 1999;105:883-93.
47. Callen E, Samper E, Ramirez MJ, et al. Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. Hum Mol Genet 2002;11:439-44.
48. Deome KB, Faulkin LJ Jr, Bern HA, Blair PB. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 1959;19:515-20.
49. Daniel CW, De Ome KB, Young JT, Blair PB, Faulkin LJ Jr. The in vivo life span of normal and preneoplastic mouse mammary glands: a serial transplantation study. Proc Natl Acad Sci U S A 1968;61:53-60.
50. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36 Suppl 1:59-72.
51. Welm B, Behbod F, Goodell MA, Rosen JM. Isolation and characterization of functional mammary gland stem cells. Cell Prolif 2003;36:17-32.